Latest Medtech News

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

Hydrix Limited has secured $5.22 million from its retail entitlement offer, leaving nearly $3 million in entitlements unsold, which will be offered separately under a shortfall offer managed by Peak Asset Management.

EBR Systems has kicked off a fully underwritten 1-for-2 entitlement offer priced at $0.38 per CDI, aiming to raise $85.6 million to accelerate commercialisation and manufacturing of its wireless cardiac pacing technology.

Hydrix Limited has launched the retail phase of its accelerated entitlement offer aiming to raise up to $8.18 million by issuing six new shares per existing share at $0.005 each, plus free options. The institutional component has closed, and retail shareholders have until 5 June to participate.

Hydrix Limited has bolstered its balance sheet by raising $3.89 million and converting $5.1 million of debt into equity, positioning itself to expand its Defence technology footprint following a $1.2 million contract with NIOA Group.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

HITIQ Limited's March quarter saw a remarkable 223% jump in sales to $294k, driven by the nationwide rollout of its PROTEQT™ concussion management system and initial international sales. The company bolstered its governance and advisory ranks while managing funding to support its commercial push.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.